Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Johnson & Johnson (JNJ) And GlaxoSmithKline PLC (ADR) (GSK) Rheumatoid Arthritis Drug Meets Targets In Large Phase 3 Study

A drug being developed jointly by Johnson & Johnson (NYSE:JNJ) and GlaxoSmithKline plc (ADR) (NYSE:GSK) met endpoints in a large Phase 3 study that enrolled 1,670 patients. The drug candidate called sirukumab is aimed at people suffering from rheumatoid arthritis and the positive late-stage data means that the developers have edged closer to its commercialization.

According to Johnson & Johnson and GSK, patients who received sirukumab treatment demonstrated significant improvement in their disease condition compared to the control group that received a placebo. Rheumatoid arthritis is characterized by joint damage caused by autoimmunity. Patients on sirukumab during the Phase 3 study not only exhibited less joint erosion, but their joint space also significantly narrowed.

Follow Johnson & Johnson (NYSE:JNJ)
Trade (NYSE:JNJ) Now!

Change in joint damage

Johnson & Johnson (NYSE:JNJ) and GlaxoSmithKline plc (ADR) (NYSE:GSK) researchers used a scoring method to determine changes in joint damage. When viewed by the aid of X-ray, a higher score indicates greater joint damage. The patients who took a placebo exhibited a score of 3.69 compared to a score of 0.50 for the patients who took 50mg of sirukumab and a score of 0.46 for those who received 100mg of the drug.

care, pharmacist, business, pill, chemist, clinic, drugstore, medicine, illness, health, indoors, prescription, healthcare, pharmaceutical, medical, retail, drug, singapore, treatment, shelf, medication, hospital, store, shop, pharmacy

Trong Nguyen / Shutterstock.com

The changes in joint structure were noted in patients who took the 50mg dose every four weeks and those who took the 100mg dose every two weeks.

Improvement in disease symptoms

According to both companies, 54.8% of the patients in the 50mg dose group registered at least 20% improvement in the disease signs and symptoms they experienced. In the group that received the 100mg dose, 53.5% of them showed more than 20% improvement in their disease condition. In contrast, just 26.4% of the placebo group exhibited an improvement in their disease symptoms.

On the average, at least 30% of all the patients who received sirukumab demonstrated 50% improvement in their disease condition.

Data presentation

Johnson & Johnson (NYSE:JNJ) and GlaxoSmithKline plc (ADR) (NYSE:GSK) researchers will present the data in London at the weekend during a European rheumatology meeting.

Follow Glaxosmithkline Plc (NYSE:GSK)
Trade (NYSE:GSK) Now!

Note: This article is written by Adam Russell and originally published at Market Exclusive.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!